Md. biotech to be acquired by New Jersey pharmaceutical goliath
Rockville-based BeneVir Biopharm Inc., a biotech specializing in immunotherapy treatments for cancer, has reached a deal to sell to pharmaceutical goliath Janssen Biotech Inc., a Johnson& Johnson company, in a deal worth up to $1.04 billion.
Janssen, based in Titusville, New Jersey, will pay BeneVir $140 million in cash upon closing of the transaction, expected in the second quarter of this year, according to a company announcement. Additional contingent payments based on the achievement of certain…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Sara Gilgore Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Health Management | Immunotherapy